The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | Using AI to predict light chain amyloidosis in patients with MGUS and SMM
Eli Muchtar
• 6 Sep 2022
Eli Muchtar, MD, Mayo Clinic, Rochester, MN, comments on the potential of artificial intelligence (AI) in predicting the risk of developing AL amyloidosis in patients with multiple myeloma precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
